- Previous Close
2.2500 - Open
2.1981 - Bid 2.0100 x --
- Ask 2.4900 x --
- Day's Range
2.0496 - 2.2000 - 52 Week Range
1.7000 - 10.0000 - Volume
184,891 - Avg. Volume
1,061,048 - Market Cap (intraday)
24.81M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
www.synairgen.comRecent News: SNG.L
View MorePerformance Overview: SNG.L
Trailing total returns as of 2/14/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNG.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNG.L
View MoreValuation Measures
Market Cap
24.81M
Enterprise Value
16.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.59
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-42.87M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
8.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--